Overview / Trans Sodium Crocetinate (TSC)

TSC is a first-in-class small molecule that, by its novel, proprietary mechanism, safely re-oxygenates oxygen-deprived tissue; it can act alone or with other treatments and it presents opportunities in unmet medical needs across $ billion markets.  TSC can be used to enhance the cancer-killing power of radiation and chemotherapy.  In our Phase 2 study, we saw a four-fold improvement in 2 year survival among newly-diagnosed, inoperable glioblastoma, paving the way for our Phase 3 registration trial, which is currently enrolling patients.

In non-oncology indications, TSC’s uses are supported by compelling clinical and preclinical data, and include our acute stroke program.  Here, in co-operation with UCLA and the U of VA, TSC will be dosed while the stroke patient is still in the ambulance. Other potential indications are heart attack, emergency medicine, respiratory and neurodegenerative diseases

We have broad protection of our patent portfolio ranging through 2031 with possible extensions to 2036  In addition Orphan Designations in the brain cancers, add an additional 7 years of exclusivity there.  An experienced management team, directors and advisors are all working together to move this opportunity to commercialization.